Rv3881c from Mycobacterium tuberculosis Elicits PolyFunctional CD8+ T cells in PPDPositive Healthy Volunteers and Affords Significant Protection in the Guinea Pig Model

Author(s):  
Satchidanandam V ◽  
Kumar N ◽  
Biswas S
2010 ◽  
Vol 79 (2) ◽  
pp. 716-723 ◽  
Author(s):  
Hongliang Yang ◽  
JoLynn Troudt ◽  
Ajay Grover ◽  
Kimberly Arnett ◽  
Megan Lucas ◽  
...  

ABSTRACTPurified protein derivative (PPD) is a widely used reagent for the diagnosis ofMycobacterium tuberculosisinfection. Recently, the molecular composition of PPD was defined, with hundreds of mycobacterial protein representatives making up PPD. Which, if any, of these specific products drive the potency of PPD remains in question. In this study, two proteins (DnaK and GroEL2) previously identified as dominant proteins in PPD were tested for the capacity to induce delayed-type hypersensitivity (DTH) responses in H37Rv-infected or BCG-vaccinated guinea pigs. These two proteins were used in pull-down assays to identify interacting PPD products. Six proteins were identified as interacting partners with DnaK and GroEL2, i.e., Rv0009, Rv0475, Rv0569, Rv0685, Rv2626c, and Rv2632c. These six proteins were tested alone and in combination with DnaK and GroEL2 for the capacity to induce a DTH response in the guinea pig model. From these studies, two cocktails, DnaK/GroEL2/Rv0009 and DnaK/GroEL2/Rv0685, were found to induce DTH responses in H37Rv-infected or BCG-vaccinated guinea pigs that were indistinguishable from DTH responses driven by a PPD injection. The mechanism by which DTH responses were induced was elucidated by histologic examination, analysis of activated CD4+/CD8+T cells, and cytokine mRNA expression at the site of the DTH response. PPD and the protein cocktails tested induced strong DTH responses in H37Rv-infected guinea pigs. Ex vivo phenotyping of T cells at the DTH site indicated that this response is mediated by activated CD4+and CD8+T cells, with increases in gamma interferon and tumor necrosis factor alpha, but not interleukin-10, at the site of the DTH response. Our results demonstrate for the first time that the PPD response can be mimicked at the molecular level with defined protein cocktails. The use of this defined product will allow a more thorough understanding of the DTH response and may provide a platform for more rapid and sensitive second-generation skin test reagents for the diagnosis ofM. tuberculosisinfection.


Tuberculosis ◽  
2017 ◽  
Vol 106 ◽  
pp. 99-105 ◽  
Author(s):  
JoLynn Troudt ◽  
Elizabeth Creissen ◽  
Linda Izzo ◽  
Helle Bielefeldt-Ohmann ◽  
Stefano Casonato ◽  
...  

2021 ◽  
Vol 1 (12) ◽  
Author(s):  
Elizabeth Creissen ◽  
Linda Izzo ◽  
Clinton Dawson ◽  
Angelo A. Izzo

Author(s):  
Zahoor Ahmad ◽  
Michael Pinn ◽  
Charles Peloquin ◽  
Eric L. Nuermberger ◽  
Jacques Grosset ◽  
...  

2009 ◽  
Vol 219 (3) ◽  
pp. 257-262 ◽  
Author(s):  
Isamu Sugawara ◽  
Tadashi Udagawa ◽  
Toshiaki Aoki ◽  
Satoru Mizuno

2008 ◽  
Vol 10 (14-15) ◽  
pp. 1469-1476 ◽  
Author(s):  
Suely S. Kashino ◽  
Danielle R. Napolitano ◽  
Ziedonis Skobe ◽  
Antonio Campos-Neto

2005 ◽  
Vol 73 (8) ◽  
pp. 4676-4683 ◽  
Author(s):  
Marcus A. Horwitz ◽  
Günter Harth ◽  
Barbara Jane Dillon ◽  
Saša Masleša-Galić

ABSTRACT Tuberculosis continues to ravage humanity, killing 2 million people yearly. Most cases occur in areas of the world to which the disease is endemic, where almost everyone is vaccinated early in life with Mycobacterium bovis BCG, the currently available vaccine against tuberculosis. Thus, while more-potent vaccines are needed to replace BCG, new vaccines are also needed to boost the immune protection of the 4 billion people already vaccinated with BCG. Until now, no booster vaccine has been shown capable of significantly enhancing the level of protective immunity induced by BCG in the stringent guinea pig model of pulmonary tuberculosis, the “gold standard” for testing tuberculosis vaccines. In this paper, we describe a booster vaccine for BCG comprising the purified recombinant Mycobacterium tuberculosis 30-kDa protein, the major secreted protein of this pathogen. In the guinea pig model of pulmonary tuberculosis, boosting BCG-immunized animals once with the 30-kDa protein greatly increased cell-mediated and humoral immune responses to the protein in three consecutive experiments. Most importantly, boosting BCG-immunized animals once with the 30-kDa protein significantly enhanced protective immunity against aerosol challenge with highly virulent M. tuberculosis, as evidenced by a significantly reduced lung and spleen burden of M. tuberculosis compared with those for nonboosted BCG-immunized animals (mean additional reduction in CFU of 0.4 ± 0.1 log in the lung [P = 0.03] and 0.6 ± 0.1 log in the spleen [P = 0.002]). This study suggests that administering BCG-immunized people a booster vaccine comprising the 30-kDa protein may enhance their level of immunoprotection against tuberculosis.


Sign in / Sign up

Export Citation Format

Share Document